Eton Pharma Q1 product sales $24.3M (+73% YoY); raises FY2026 guidance to >$120M

Eton Pharmaceuticals, Inc.

2026-Q1 EPS reported $0.05 revenue$24,266,000

Q1 product sales $24.3M (+73% YoY); GAAP diluted EPS $0.05, non-GAAP diluted EPS $0.14, Adj. EBITDA $5.7M (24% margin)
Raises full-year 2026 revenue guidance to >$120M from prior $110M; expects ≥30% Adj. EBITDA margin
Launched DESMODA (FDA-approved oral desmopressin solution); acquired and relaunched HEMANGEOL on May 1
Initiated ET-700 clinical study (extended-release zinc acetate for Wilson disease); FDA cleared INCRELEX label harmonization study
Net income of $1.6M vs net loss of $1.6M in Q1 2025; cash $19.7M after $14M HEMANGEOL acquisition

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eton Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: revenue $24.3 million, EPS $0.05. Guidance raised.

Period: the quarter ended March 31, 2026
Revenue: $24.3 million
EPS: $0.05
Guidance: raised
Result: reported results

Exact text from the filing

Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 ● Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million ● Q1 2026 fully diluted GAAP EPS of $0.05

View on SEC.gov

Browse all earnings releases →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-017063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.